Journal Watch · BMJ · 2026

Time trends in newly recorded diagnoses of 19 long term conditions before, during, and after the covid-19 pandemic: population based cohort study in England using OpenSAFELY.

This study highlights the potential for near real time monitoring of disease epidemiology using routinely collected health data, informing strategies to enhance case detection and investigate inequities in healthcare.

Russell MD, Schaffer A, Bechman K et al.BMJ4 min readPharma relevance 40/100

DOI: 10.1136/bmj-2025-086393PMID: 41565343Study type: cohort / observational clinical study

TL;DR

This study highlights the potential for near real time monitoring of disease epidemiology using routinely collected health data, informing strategies to enhance case detection and investigate inequities in healthcare.

Key findings

  • Unadjusted subgroup analyses stratified by ethnicity and socioeconomic status indicated that, after an initial decrease, dementia diagnosis rates have risen above pre-pandemic levels for people of white ethnicity and in less deprived socioeconomic areas, but not for those from other ethnicities and more deprived areas.<h4>Conclusions</h4>Since the covid-19 pandemic, there have been fewer diagnoses than expected for conditions such as depression, asthma, COPD, and osteoporosis, in contrast with a rapid increase in diagnoses of chronic kidney disease since 2022.
  • Unadjusted analyses stratified by ethnicity and socioeconomic status suggest differential patterns of recovery, particularly for individuals with dementia.
  • This study highlights the potential for near real time monitoring of disease epidemiology using routinely collected health data, informing strategies to enhance case detection and investigate inequities in healthcare.

Numbers at a glance (from the abstract)

27.7%95%16.4%15.8%17.1%11.5%34.8%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

As of November 2024, cumulative reductions in diagnoses remained evident for conditions such as depression (734 800 (27.7%) fewer diagnoses than expected; 95% prediction interval (PI) 703 100 to 766 400), asthma (152 900 (16.4%) fewer diagnoses; 95% PI 137 500 to 168 300), chronic obstructive pulmonary disease (COPD) (90 100 (15.8%) fewer diagnoses; 95% PI 81 400 to 98 900), psoriasis (54 700 (17.1%) fewer diagnoses; 95% PI 50 100 to 59 200), and osteoporosis (54 100 (11.5%) fewer diagnoses; 95% PI 47 100 to 61 100). Conversely, diagnoses of chronic kidney disease have increased by 34.8% above expected levels during the pandemic recovery period, corresponding to 359 000 additional diagnoses (95% PI 333 500 to 384 500).

Full abstract (original)

Background: <h4>Objective</h4>To evaluate temporal changes in rates of newly recorded diagnoses for 19 long term conditions in England in relation to the covid-19 pandemic by disease, age group, sex, socioeconomic status, and ethnicity.<h4>Design</h4>Population based cohort study.<h4>Setting</h4>Primary care and hospital admission data, with the approval of NHS England.<h4>Participants</h4>29 995 025 individuals registered with general practices in England contributing data to the OpenSAFELY-TPP platform.<h4>Main outcome measures</h4>Temporal trends in age and sex standardised incident and prevalent diagnosis rates for 19 long term conditions between 1 April 2016 and 30 November 2024. Differences between expected and observed diagnosis rates after the onset of the covid-19 pandemic were compared using seasonal autoregressive integrated moving-average models, based on modelled projections of expected rates from pre-pandemic patterns.<h4>Results</h4>All 19 conditions showed a sharp decline in newly recorded diagnoses during the first year of the pandemic, followed by variable recovery.

What they did: As of November 2024, cumulative reductions in diagnoses remained evident for conditions such as depression (734 800 (27.7%) fewer diagnoses than expected; 95% prediction interval (PI) 703 100 to 766 400), asthma (152 900 (16.4%) fewer diagnoses; 95% PI 137 500 to 168 300), chronic obstructive pulmonary disease (COPD) (90 100 (15.8%) fewer diagnoses; 95% PI 81 400 to 98 900), psoriasis (54 700 (17.1%) fewer diagnoses; 95% PI 50 100 to 59 200), and osteoporosis (54 100 (11.5%) fewer diagnoses; 95% PI 47 100 to 61 100). Conversely, diagnoses of chronic kidney disease have increased by 34.8% above expected levels during the pandemic recovery period, corresponding to 359 000 additional diagnoses (95% PI 333 500 to 384 500).

Results & conclusions: Unadjusted subgroup analyses stratified by ethnicity and socioeconomic status indicated that, after an initial decrease, dementia diagnosis rates have risen above pre-pandemic levels for people of white ethnicity and in less deprived socioeconomic areas, but not for those from other ethnicities and more deprived areas.<h4>Conclusions</h4>Since the covid-19 pandemic, there have been fewer diagnoses than expected for conditions such as depression, asthma, COPD, and osteoporosis, in contrast with a rapid increase in diagnoses of chronic kidney disease since 2022. Unadjusted analyses stratified by ethnicity and socioeconomic status suggest differential patterns of recovery, particularly for individuals with dementia. This study highlights the potential for near real time monitoring of disease epidemiology using routinely collected health data, informing strategies to enhance case detection and investigate inequities in healthcare.

Abstract © the authors / BMJ (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1136/bmj-2025-086393 · PubMed 41565343.

Why it matters for pharma & biotech

  • Relevant to General & Medicine teams tracking BMJ for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this BMJ study find?

This study highlights the potential for near real time monitoring of disease epidemiology using routinely collected health data, informing strategies to enhance case detection and investigate inequities in healthcare.

What type of study is this?

It is a cohort / observational clinical study, published in BMJ in 2026. As of November 2024, cumulative reductions in diagnoses remained evident for conditions such as depression (734 800 (27.7%) fewer diagnoses than expected; 95% prediction interval (PI) 703 100 to 766 400), asthma (152 900 (16.4%) fewer diagnoses; 95% PI 137 500 to 168 300), chronic obstructive pulmonary disease (COPD) (90 100 (15.8%) fewer diagnoses; 95% PI 81 400 to 98 900), psoriasis (54 700 (17.1%) fewer diagnoses; 95% PI 50 100 to 59 200), and osteoporosis (54 100 (11.5%) fewer diagnoses; 95% PI 47 100 to 61 100).

Where can I read the original paper?

The original is at the publisher via DOI 10.1136/bmj-2025-086393. PubMed ID: 41565343. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Russell MD, Schaffer A, Bechman K et al.. Time trends in newly recorded diagnoses of 19 long term conditions before, during, and after the covid-19 pandemic: population based cohort study in England using OpenSAFELY.. BMJ (2026). DOI: 10.1136/bmj-2025-086393.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/time-trends-in-newly-recorded-diagnoses-of-19-long-term-conditions-befor-086393/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides